EP1701937A1 - Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide - Google Patents

Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide

Info

Publication number
EP1701937A1
EP1701937A1 EP03768046A EP03768046A EP1701937A1 EP 1701937 A1 EP1701937 A1 EP 1701937A1 EP 03768046 A EP03768046 A EP 03768046A EP 03768046 A EP03768046 A EP 03768046A EP 1701937 A1 EP1701937 A1 EP 1701937A1
Authority
EP
European Patent Office
Prior art keywords
dihydroxy
diethyl
cyano
nitrophenyl
acrylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03768046A
Other languages
German (de)
English (en)
Other versions
EP1701937A4 (fr
Inventor
Siddiqui Mohammed Wockhardt Ltd JAWEED MUKARRAM
Rashid Abdul Rehman Wockhardt Ltd. KHAN
Ram Prasad Wockhardt Ltd. YADAV
Zakir Gafoor Wockhardt Ltd. SHAIKH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAWEED MUKARRAM, SIDDIQUI MOHAMMED
Khan Rashid Abdul Rehman
Shaikh Zakir Gafoor
YAVAD, RAM PRASAD
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of EP1701937A1 publication Critical patent/EP1701937A1/fr
Publication of EP1701937A4 publication Critical patent/EP1701937A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to stable crystalline polymorphic forms C and D of (E)- N,N- iethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (Entacapone) and their efficient preparation processes.
  • Polymorphic Form C of Entacapone (E)-isomer is obtained by simple work-up procedure while Form D by converting Form A or Form C of Entacapone.
  • Polymorphic form C and D of (E)-Entacapone are characterized by specific Jjnfra Red (IR) and X-ray powder diffraction peak values.
  • (E)- isomer of Entacapone is an excellent inhibitor of Catechol-O-methyl transferase (COMT) enzyme.
  • Entacapone N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophe- nyl)acrylamide.
  • British patent application No. 8,727,854 describes Entacapone as a potent inhibitor of catechol-O-methyl-transferase (COMT) enzyme. The product is indicated for the treatment of Parkinson's disease.
  • Catechol-O-methyltransferase (COMT) catalyzes the methyl group from s-adenosyl-L-methionine to a number of compounds with catechol structures. This enzyme is important in the extraneuronal inactivation of catecholamines and drugs with catechol structures.
  • COMT is one of the most important enzyme involved in the metabolism of catecholamines. It is find in the most tissues, both in periphery and the central nervous system. The highest activities are found in the liver, intestine and kidney.
  • the said method allows large scale production of homogeneous and crystallographically essentially pure polymorphic form A of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl)acrylamide.
  • “Crystallographically essentially pure” means the polymorphic form A of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide containing a maximum of 3 % and preferably a maximum of 2 % of the Z-isomer.
  • Entacapone is widely used as an excellent potent inhibitor of Catechol-O-methyl transferase enzyme.
  • the present invention discloses manufacturing processes of new polymorphic Forms C and D of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)- acrylamide.
  • Form C may be obtained in high purity without isolating crude solid of isomeric mixture of N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nirrophenyl)acrylamide, directly by simple crystallization technique.
  • the present invention is directed to an anti-Catechol-O-methyl-transferase compound having therapeutic value and processes for their manufacture.
  • the invention is directed to the new crystallographically pure polymo ⁇ hic Form C and D of (E)- N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (Entacapone) having Formula I,
  • the invention is directed to a process for the manufacture of (E)-Entacapone Form C, comprising reacting 3,4-dihydroxy-5-nitrobenzaldehyde withN,N- Diethylcyanoacetamide in presence of a base in alcohol followed by treatment with acetic acid and crystallization with a mixture of alcohols.
  • the invention is directed to the preparation process of (E)- Entacapone Form D.
  • the polymrohic Form D is prepared by converting polymorphic form A or C of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide.
  • the purity of these new polymo ⁇ hic forms C and D has been assessed by HPLC while characterized by Infra Red Spectroscopy and X-Ray powder diffraction (XRD) techniques.
  • the present invention relates to an anti-Catechol-O-methyl transferase compound in different polymo ⁇ hic forms having therapeutic value and processes for their manufacture.
  • the present invention is directed to the new polymo ⁇ hic Forms C and D of (E)- N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and processes for the preparation of such compound in different polymo ⁇ hic forms.
  • the present invention provides a method for the manufacture of new polymo ⁇ hic Form C of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide.
  • the product is obtained in highly pure form using absolute alcohol without isolating crude solid.
  • the present invention provides a number of methods to develop polymo ⁇ hic Form D of (E)-Entacapone using different solvent combinations.
  • the processes comprise by dissolving "crystallographically pure Form A” or “crystallographically essentially pure Form A” or "Form C" in lower carboxylic acid or highly polar water miscible organic solvent or mixtures thereof.
  • a process for the manufacture of (E)-N,N-Diethyl-2- cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide which comprises the condensation of 3,4- Dihydroxy-5-nitrobenzaldehyde (Formula II) with N,N-Diethylcyanoacetamide (Formula III) in presence of a base in alcoholic solution.
  • Suitable solvent for this synthetic stage include, but are not limited to, aliphatic alcohols, e.g., methanol, ethanol, isopropanol, isobutanol or n-butanol more particularly in isopropanol or ethanol.
  • Suitable bases include, but not limited to, amines, e.g., piperidine, N- methylmo ⁇ holine, mo ⁇ holine, pyridine or piperazine more preferably piperidine. After completion of the reaction aliphatic acid more preferably acetic acid is added to the reaction mixture.
  • Crystallographically pure Form C of (E)-N,N-Diethyl-2-cyano- 3-(3,4-dihydroxy-5-nitrophenyl)acrylamide is dissolved in aliphatic alcohol more preferably in ethanol to get the clear solution.
  • the solution is added to vigorously stirred chilled water and stirred additionally for about 1 to about 5 hours.
  • Title product is isolated by filtration, washing with water and isopropyl ether followed by vacuum drying.
  • (E)-Entacapone Form D thus obtained is crystalline in nature in 88 % yield.
  • Crystallographically essentially pure Form A of (E)-N,N- Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide is dissolved in sulfoxides preferably in Dimethylsulfoxide. The solution is added to vigorously stirred chilled water and stirred additionally for about 1 to about 5 hours additionally. Title product is isolated by filtration, washing with water and isopropyl ether followed by vacuum drying. (E)- Entacapone Form D thus obtained is crystalline form in about 91 % yield and in more than 99 % HPLC purity.
  • Crystalline Form C and D of (E)-N, N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrop- henyl)acrylamide has been characterized by Infra Red (LR) Spectrum, X-Ray powder diffraction (XRD)and melting points and their purity is tested HPLC. For comparison pu ⁇ oses, certain of these analyses have also been performed for the corresponding polymo ⁇ hic form A of Entacapone.
  • Figures 2 and 3 show Infra Red abso ⁇ tion bands for the polymo ⁇ hic forms C and D of (E)- N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide, respectively.
  • IR Pealcs for Entacapone Form A is referred from US Patent 5,135,590 for comparison purpose.
  • a comparison of IR peak values of polymo ⁇ hic forms of (E)-Entacapone is set forth in Table 1.
  • X-Ray Powder Diffraction Figures 4 and 5 show X-ray powder diffraction pattern for the polymo ⁇ hic form C and D of (E)- N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide, respectively.
  • a comparison of the complete diffraction peaks, designated by "2 ⁇ " and expressed in degrees, is set forth in Table 2.
  • Crystallographically pure (E)-N,N-Diethyl-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)- acrylamide Form D Crystallographically pure form A of (E)-N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5- nitrophenyl)acrylamide ( 5.0 gm) is dissolved in N,N-dimethylformamide (25 ml) to make a clear solution. The solution is added slowly and carefully to vigorously stirred chilled water (200 ml). Stirring is continued for further two hours to get the precipitate. Precipitated product is isolated by filtration followed by washing with water and isopropyl ether. The title product thus obtained is dried under vacuum to obtain in crystalline form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne les polymorphes cristallins stables C et D de (E)-N,N-diéthyl-2-cyan-3-(3,4-dihydroxy-5-nitrophényl)acrylamide (Entacapone) et leur préparation. (E)-Entacapone de forme C est obtenue par condensation de 3,4-dihydroxy-5-nitrobenzaldehyde et N,N-diéthylcyanoacetamide en présence d'une base suivi par l'addition de l'acide acétique après la réaction et une cristallisation subséquente. (E)-Entacapone de forme D est obtenue à partir de l'entacapone de forme C, (E)-entacapone de forme A pur ou sensiblement pur d'un point de vue cristallographique. Les polymorphes C et D de (E)-entacapone sont caractérisées par valeurs crêtes d'infra rouge (IR) et diffraction des rayons X sur poudre.
EP03768046A 2003-12-29 2003-12-29 Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide Ceased EP1701937A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/006200 WO2005066117A1 (fr) 2003-12-29 2003-12-29 Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide

Publications (2)

Publication Number Publication Date
EP1701937A1 true EP1701937A1 (fr) 2006-09-20
EP1701937A4 EP1701937A4 (fr) 2007-05-02

Family

ID=34746624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03768046A Ceased EP1701937A4 (fr) 2003-12-29 2003-12-29 Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide

Country Status (5)

Country Link
EP (1) EP1701937A4 (fr)
AU (1) AU2003292465A1 (fr)
BR (1) BR0318690A (fr)
CA (1) CA2551791A1 (fr)
WO (1) WO2005066117A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945607B1 (fr) * 2005-11-09 2009-10-14 USV Limited Procédé pour la préparation de (e)-n,n-diéthyl-2-cyano-3-(3,4-dihydroxy-5-nitrophényl)acrylamide (entacapone) extrêmement pur
US20080300420A1 (en) * 2006-01-02 2008-12-04 Sanmar Speciality Chemicals Ltd. Process for the Preparation of Entacapone Form-A
US7932415B2 (en) * 2006-02-06 2011-04-26 Orion Corporation Process for manufacturing entacapone
GB0610207D0 (en) * 2006-05-23 2006-07-05 Pliva Istrazivanje I Razvoj D New forms of active pharmaceutical ingredient
WO2008023380A1 (fr) * 2006-08-24 2008-02-28 Srinivasa Reddy Battula PROCÉDé AMÉLioré ET SIMPLIFIÉ POUR LA PRÉPARATION DU (E) N,N-DIÉTHYL-2-CYANO-3-(3,4-DIHYDROXY-5-NITROPHéNYL)ACRYLAMiDE
ES2306587B1 (es) * 2006-11-15 2009-08-07 Quimica Sintetica, S.A. Nueva forma cristalina de entacapona y procedimiento para su obtencion.
ES2319024B1 (es) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200109A (en) * 1986-11-28 1988-07-27 Orion Yhtymae Oy Catechol derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2238047B (en) * 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200109A (en) * 1986-11-28 1988-07-27 Orion Yhtymae Oy Catechol derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2005066117A1 *

Also Published As

Publication number Publication date
AU2003292465A1 (en) 2005-08-12
WO2005066117A1 (fr) 2005-07-21
CA2551791A1 (fr) 2005-07-21
EP1701937A4 (fr) 2007-05-02
BR0318690A (pt) 2006-12-26

Similar Documents

Publication Publication Date Title
EP0426468B1 (fr) Forme polymorphe stable de (E)-N,N-diéthyl-2-cyano-3-(3,4-dihydroxy-5-nitrophényl) acrylamide et procédé pour sa préparation
US20070004935A1 (en) Efficient method for the manufacture of (E) -Entacapone polymorphic Form A
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
US20070060767A1 (en) Methods for the preparation of Entacapone
US20110263719A1 (en) Polymorphic form of rasagiline mesylate
CN110891947B (zh) 制备艾乐替尼或其药学上可接受的盐的方法
WO2005066117A1 (fr) Polymorphes stables de (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
JP2006528203A (ja) レバルブテロールヒドロクロリド多形ａ
JP2005507858A (ja) ザレプロンを生産する方法
US20080300420A1 (en) Process for the Preparation of Entacapone Form-A
WO2006064296A1 (fr) Procede de preparation du (e)-n1n- diethyl-2-cyano-3-(3,4-dihydroxy-t5-nitro-phenyl)-acrylamide sous une forme polymorphe stable et des intermediaires du procede
US7728173B2 (en) Processes for preparing venlafaxine and venlafaxine hydrochloride of form I
US20080004343A1 (en) Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
US20090312575A1 (en) Process For Preparing A Benzoylbenzeneacetamide Derivative
US20100104649A1 (en) Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate
EP2251323B1 (fr) Procédé de purification d'entacapone
WO2007096904A2 (fr) Procédé amélioré de préparation d'hydrochlorure de terbinafine et nouvelle forme cristallin de terbinafine
JP4550740B6 (ja) エンタカポンの改良製造方法
JP2007519700A6 (ja) Ｎ−［３−（３−シアノピラゾロ［１，５−ａ］ピリミジン−７−イル）−フェニル］−Ｎ−エチル−アセタミドの合成方法
EP2275410A1 (fr) Processus pour la production d un composé présentant une activité antagoniste sur le récepteur npyy5, et cristal utile
JP2022514782A (ja) 化合物の製造、その新しい塩形態および治療的使用
US20090177010A1 (en) Process of making sertraline form i
WO2008058992A1 (fr) Nouvelle forme cristalline de l'entacapone et son procédé de préparation
JP2012500251A (ja) ４−［トランス−４−［（フェニルメチル）アミノ］シクロヘキシル］安息香酸のエチルエステルおよびこのヘミフマル酸塩の調製方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070329

17Q First examination report despatched

Effective date: 20080128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WOCKHARDT LIMITED

Owner name: JAWEED MUKARRAM, SIDDIQUI MOHAMMED

Owner name: KHAN, RASHID ABDUL REHMAN

Owner name: YAVAD, RAM PRASAD

Owner name: SHAIKH, ZAKIR GAFOOR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20141208